Shanghai Junshi Biosciences Co Ltd - Asset Resilience Ratio

Latest as of December 2025: 4.85%

Shanghai Junshi Biosciences Co Ltd (688180) has an Asset Resilience Ratio of 4.85% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Shanghai Junshi Biosciences Co Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

CN¥600.81 Million
≈ $87.92 Million USD Cash + Short-term Investments

Total Assets

CN¥12.38 Billion
≈ $1.81 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2025)

This chart shows how Shanghai Junshi Biosciences Co Ltd's Asset Resilience Ratio has changed over time. See Shanghai Junshi Biosciences Co Ltd (688180) net asset quality to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Junshi Biosciences Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688180 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥600.81 Million 4.85%
Total Liquid Assets CN¥600.81 Million 4.85%

Asset Resilience Insights

  • Limited Liquidity: Shanghai Junshi Biosciences Co Ltd maintains only 4.85% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Junshi Biosciences Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Junshi Biosciences Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 10.93%
CSL Ltd
AU:CSL
Biotechnology 0.41%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 57.90%
HLB Co. Ltd
KQ:028300
Biotechnology 0.72%
SOLENO THERAPEUT. DL-001
F:6XC
Biotechnology 41.74%
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Biotechnology 87.20%
Tourmaline Bio Inc.
NASDAQ:TRML
Biotechnology 77.17%
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
Biotechnology 16.35%

Annual Asset Resilience Ratio for Shanghai Junshi Biosciences Co Ltd (2014–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai Junshi Biosciences Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 4.85% CN¥600.81 Million
≈ $87.92 Million
CN¥12.38 Billion
≈ $1.81 Billion
+0.87pp
2024-12-31 3.99% CN¥430.51 Million
≈ $63.00 Million
CN¥10.80 Billion
≈ $1.58 Billion
+3.99pp
2020-12-31 0.00% CN¥17.00K
≈ $2.49K
CN¥8.01 Billion
≈ $1.17 Billion
0.00pp
2019-12-31 0.00% CN¥17.00K
≈ $2.49K
CN¥4.42 Billion
≈ $647.14 Million
-0.13pp
2018-12-31 0.13% CN¥5.52 Million
≈ $807.16K
CN¥4.26 Billion
≈ $622.98 Million
-11.96pp
2017-12-31 12.09% CN¥147.43 Million
≈ $21.57 Million
CN¥1.22 Billion
≈ $178.48 Million
-20.42pp
2016-12-31 32.50% CN¥373.47 Million
≈ $54.65 Million
CN¥1.15 Billion
≈ $168.14 Million
-38.21pp
2014-12-31 70.71% CN¥235.44 Million
≈ $34.45 Million
CN¥332.94 Million
≈ $48.72 Million
--
pp = percentage points

About Shanghai Junshi Biosciences Co Ltd

SHG:688180 China Biotechnology
Market Cap
$3.34 Billion
CN¥22.80 Billion CNY
Market Cap Rank
#4719 Global
#843 in China
Share Price
CN¥29.78
Change (1 day)
-1.39%
52-Week Range
CN¥28.93 - CN¥48.80
All Time High
CN¥151.00
About

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more